3 completed, 1 recruiting, 1 unknown. 5 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Lung Infection: new trials by email Literature Review of Lung Infection trials Research Report on Lung Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia Opaganib, Placebo - COVID-19, Lung Infection | Phase 2 / Phase 3 | Completed | RedHill Biopharma Limited | 475 | 2020-08-21 | 2025-07-31 |
| Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 AR-301, Placebo - Lung Infection, Pneumonia, Ventilator-Associated | Phase 3 | Completed | Aridis Pharmaceuticals, Inc. | 174 | 2019-05-03 | 2023-07-06 |
| CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections Clarithromycin 1000 MG, Azithromycin 250 mg, Rifampicin - Lung Infection, MAC Lung Disease | Phase 3 | Recruiting | Centre Hospitalier Universitaire, Amiens | 424 | 2018-02-05 | 2025-11-19 |
| Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From Cerebral Hemorrhage rhubarb, Placebo - Lung Infection, Cerebral Hemorrhage | Phase 2 / Phase 3 | Unknown | Fudan University | 100 | 2009-01-01 | 2010-05-28 |
| Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa AZLI 75 mg three times daily (TID), Placebo three times daily (TID) - Cystic Fibrosis, Lung Infection | Phase 3 | Completed | Gilead Sciences | 160 | 2008-05-01 | 2010-12-20 |
Pneumonia (2) · Bacterial Infections (1) · COVID-19 (1) · Cerebral Hemorrhage (1) · Cystic Fibrosis (1) · Infections (1) · Pneumonia, Ventilator-Associated (1) · Pseudomonas Infections (1) · Staphylococcal Infections (1)
Lung Diseases (4) · Respiratory Tract Diseases (4) · Infections (3) · Respiratory Tract Infections (3) · Bacterial Infections and Mycoses (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bacterial Infections (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Coronaviridae Infections (1) · Coronavirus Infections (1)
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (1) · Azithromycin (1) · Clarithromycin (1) · Ethambutol (1) · Rifampin (1) · rhubarb peony decoction (1)
Aridis Pharmaceuticals, Inc. (1) · Centre Hospitalier Universitaire, Amiens (1) · Fudan University (1) · Gilead Sciences (1) · RedHill Biopharma Limited (1)
Brazil (2) · China (2) · France (2) · Israel (2) · Mexico (2) · Russia (2) · United States (2) · Australia (1) · Belarus (1) · Belgium (1) · Canada (1) · Colombia (1) · Estonia (1) · Georgia (1) · Italy (1)
Claire Wainwright, MD (1) · Hasan S Jafri, MD, FAAP (1) · Mark L Levitt, MD (1) · Ron Gibson, MD (1)